Nippon Kayaku Gets Japanese Approval Of Hycamtin For Pediatric Malignant Solid Tumors
This article was originally published in PharmAsia News
Nippon Kayaku’s Hycamtin obtained approval in Japan for the additional indication of pediatric malignant solid tumors, the company announced on June 14.
You may also be interested in...
Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.
NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.